Electromed (ELMD) vs. Its Rivals Financial Analysis

Electromed (NYSE: ELMD) is one of 59 public companies in the “Electromedical equipment” industry, but how does it compare to its rivals? We will compare Electromed to related businesses based on the strength of its earnings, valuation, risk, profitability, analyst recommendations, institutional ownership and dividends.


This table compares Electromed and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Electromed 12.82% 14.48% 13.01%
Electromed Competitors -310.31% -90.21% -20.70%

Valuation & Earnings

This table compares Electromed and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Electromed $32.47 million $4.16 million 19.04
Electromed Competitors $1.01 billion $120.03 million 24.20

Electromed’s rivals have higher revenue and earnings than Electromed. Electromed is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Electromed has a beta of 0.32, indicating that its stock price is 68% less volatile than the S&P 500. Comparatively, Electromed’s rivals have a beta of 24.48, indicating that their average stock price is 2,348% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for Electromed and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Electromed 0 0 0 0 N/A
Electromed Competitors 338 1000 1695 86 2.49

As a group, “Electromedical equipment” companies have a potential upside of 6.13%. Given Electromed’s rivals higher possible upside, analysts clearly believe Electromed has less favorable growth aspects than its rivals.

Institutional and Insider Ownership

41.7% of Electromed shares are owned by institutional investors. Comparatively, 45.2% of shares of all “Electromedical equipment” companies are owned by institutional investors. 19.6% of Electromed shares are owned by company insiders. Comparatively, 16.4% of shares of all “Electromedical equipment” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.


Electromed rivals beat Electromed on 6 of the 10 factors compared.

Electromed Company Profile

Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of all ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products primarily to home health care market for patients with bronchiectasis, cystic fibrosis, and neuromuscular disease. Electromed, Inc. markets its products primarily to physicians and health care providers, as well as directly to patients. The company was founded in 1992 and is headquartered in New Prague, Minnesota.

Receive News & Ratings for Electromed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Electromed and related companies with MarketBeat.com's FREE daily email newsletter.